📊 CLDWW Key Takeaways
Is Calidi Biotherapeutics, Inc. (CLDWW) a Good Investment?
Calidi Biotherapeutics is a pre-revenue biotech company with severe cash burn and deteriorating financial fundamentals. With only $45K in revenue against $15.8M in operating losses and $16.2M in negative operating cash flow, the company is burning through capital at an unsustainable rate. Despite adequate liquidity currently, the operational trajectory is deeply concerning with no clear path to profitability.
Calidi Biotherapeutics shows extremely weak fundamentals, with de minimis revenue, deeply negative operating and net margins, and continued cash burn that far exceeds its current cash balance. While leverage is low and the current ratio is above 2x, the business appears dependent on external financing because operations are not self-sustaining and profitability remains far out of reach.
Why Buy Calidi Biotherapeutics, Inc. Stock? CLDWW Key Strengths
- Current liquidity position with $10.4M in cash provides near-term runway
- Low debt burden with debt-to-equity ratio of 0.09x limits leverage risk
- Current ratio of 2.12x indicates ability to meet short-term obligations
- Positive stockholders' equity of $6.92M supports the balance sheet
- Cash and equivalents of $10.38M provide near-term liquidity
- Low debt burden with debt-to-equity of 0.09x limits balance-sheet leverage risk
CLDWW Stock Risks: Calidi Biotherapeutics, Inc. Investment Risks
- Massive operating losses of $15.8M on only $45K revenue indicates negligible commercialization progress
- Free cash flow of -$16.2M annually will deplete $10.4M cash reserves within 6-8 months without capital raise
- Negative operating margin of -35,053% and negative ROE of -229% demonstrate severe value destruction
- No insider buying activity in past 90 days suggests lack of confidence from management
- Pre-revenue stage company with clinical-stage risk profile typical of failed biotech programs
- Revenue base is negligible at $45K, indicating very weak commercial traction
- Operating cash flow of -$16.25M suggests less than a year of cash runway without new funding
- Severely negative profitability metrics including ROE of -229.1% and ROA of -113.0% reflect poor capital efficiency
Key Metrics to Watch
- Cash runway and timing of next capital requirement
- Monthly cash burn rate and ability to extend runway
- Clinical trial progress and regulatory milestones for pipeline programs
- Revenue recognition from any licensing or partnership deals
- Operating cash flow trajectory
- Quarterly operating cash burn relative to cash balance
- Revenue growth and progress toward narrowing operating losses
Calidi Biotherapeutics, Inc. (CLDWW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.12x current ratio provides a solid financial cushion.
CLDWW Profit Margin, ROE & Profitability Analysis
CLDWW vs Healthcare Sector: How Calidi Biotherapeutics, Inc. Compares
How Calidi Biotherapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Calidi Biotherapeutics, Inc. Stock Overvalued? CLDWW Valuation Analysis 2026
Based on fundamental analysis, Calidi Biotherapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Calidi Biotherapeutics, Inc. Balance Sheet: CLDWW Debt, Cash & Liquidity
CLDWW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Calidi Biotherapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-35.70 indicates the company is currently unprofitable.
CLDWW Revenue Growth, EPS Growth & YoY Performance
CLDWW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $45.0K | -$2.0M | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Calidi Biotherapeutics, Inc. Dividends, Buybacks & Capital Allocation
CLDWW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Calidi Biotherapeutics, Inc. (CIK: 0001855485)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLDWW
What is the AI rating for CLDWW?
Calidi Biotherapeutics, Inc. (CLDWW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLDWW's key strengths?
Claude: Current liquidity position with $10.4M in cash provides near-term runway. Low debt burden with debt-to-equity ratio of 0.09x limits leverage risk. ChatGPT: Positive stockholders' equity of $6.92M supports the balance sheet. Cash and equivalents of $10.38M provide near-term liquidity.
What are the risks of investing in CLDWW?
Claude: Massive operating losses of $15.8M on only $45K revenue indicates negligible commercialization progress. Free cash flow of -$16.2M annually will deplete $10.4M cash reserves within 6-8 months without capital raise. ChatGPT: Revenue base is negligible at $45K, indicating very weak commercial traction. Operating cash flow of -$16.25M suggests less than a year of cash runway without new funding.
What is CLDWW's revenue and growth?
Calidi Biotherapeutics, Inc. reported revenue of $45.0K.
Does CLDWW pay dividends?
Calidi Biotherapeutics, Inc. does not currently pay dividends.
Where can I find CLDWW SEC filings?
Official SEC filings for Calidi Biotherapeutics, Inc. (CIK: 0001855485) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLDWW's EPS?
Calidi Biotherapeutics, Inc. has a diluted EPS of $-6.40.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CLDWW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Calidi Biotherapeutics, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CLDWW stock overvalued or undervalued?
Valuation metrics for CLDWW: ROE of -229.1% (sector avg: 15%), net margin of -35,222.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CLDWW stock in 2026?
Our dual AI analysis gives Calidi Biotherapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CLDWW's free cash flow?
Calidi Biotherapeutics, Inc.'s operating cash flow is $-16.2M, with capital expenditures of N/A. FCF margin is -36,108.9%.
How does CLDWW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -35,222.2% (avg: 12%), ROE -229.1% (avg: 15%), current ratio 2.12 (avg: 2).